Cheryl Burgess, MD
Procedural Dermatology · Washington, DCNPI 1881756872
Payments from drug & device makers
Across 548 payments — averaging $4294.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.5M
- Merz North America, Inc.$567K
- Janssen Research & Development, LLC$74K
- Aclaris Therapeutics, Inc.$69K
- Journey Medical Corporation$64K
- Incyte Corporation$35K
- plus $34K from 15 others
Across 14 payments — averaging $112.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$335,33075%
- Speaking & faculty fees$48,20511%
- Travel & lodging$35,0438%
- Food & beverage$13,1223%
- Education$640%
- Gifts$13,5773%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 250 | $1,511,538 |
| Merz North America, Inc. | 138 | $566,782 |
| Janssen Research & Development, LLC | 17 | $74,133 |
| Aclaris Therapeutics, Inc. | 16 | $68,530 |
| Journey Medical Corporation | 4 | $63,711 |
| Incyte Corporation | 44 | $35,128 |
| Pfizer | 5 | $14,081 |
| UCB, Inc. | 2 | $12,280 |
| Strata Skin Sciences, Inc. | 6 | $2,178 |
| Janssen Scientific Affairs, LLC | 1 | $2,013 |
| Medimetriks Pharmaceuticals, Inc. | 38 | $1,047 |
| Endo Pharmaceuticals Inc. | 2 | $826 |
| Regeneron Healthcare Solutions, Inc. | 5 | $403 |
| Sanofi | 2 | $401 |
| Galderma Laboratories, L.p. | 7 | $134 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $109 |
| Almirall LLC | 2 | $73 |
| Revance Therapeutics, Inc. | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$47,828
- OPZELURA$31,097
- BOTOX$21,864
- NATRELLE SALINE-FILLED BREAST IMPLANTS$15,819
- BOTOX COSMETIC$5,916
- Skyrizi$5,430
- Rinvoq$2,715
- Tremfya$2,013
- XTRAC$1,966
- ESKATA$500
- Neo-Synalar$377
- DUPIXENT$292
- ASCLERA$250
- Clindacin ETZ$153
How this compares
Too few procedural dermatology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 20 | $1,200 |
| Minoxidil | 36 | $520 |
| MethotrexateMethotrexate Sodium | 13 | $111 |
Paid to pharmacies, not to this prescriber.
Other procedural dermatology in Washington
- Sara HoganWashington$32K
- Nina HartmanWashington$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.